Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial

David Mataix-Cols*, Cynthia Turner, Benedetta Monzani, Kayoko Isomura, Caroline Murphy, Georgina Krebs, Isobel Heyman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

56 Citations (Scopus)

Abstract

A partial N-methyl-D-aspartate agonist, D-cycloserine, enhances fear extinction when given before or shortly after exposure to feared stimuli in animals. In this pilot double-blind placebo-controlled trial (trial number: ISRCTN70977225), 27 youth with obsessive-compulsive disorder were randomised to either 50mg D-cycloserine or placebo administered immediately after each of ten cognitive-behavioural therapy (CBT) sessions, primarily consisting of exposure and ritual prevention. Both groups improved significantly and maintained their gains at 1-year follow-up, with no significant advantage of D-cycloserine over placebo at any time point. The effects of CBT may not be augmented or accelerated when D-cycloserine is administered after sessions.

Original languageEnglish
Pages (from-to)77-78
Number of pages2
JournalBritish Journal of Psychiatry
Volume204
Issue number1
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Dive into the research topics of 'Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: Pilot randomised controlled trial'. Together they form a unique fingerprint.

Cite this